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Results | Of 55 212 deaths from infective endocarditis, 5607 (10.2%) occurred in PWID. Infective endocarditis deaths among PWID increased 3-fold from 1999 (n = 249) to 2016 (n = 746) (Figure 1 ), compared with a 1.5-fold increase in deaths caused by infective endocarditis in general. The proportion of infective endocarditis deaths in PWID increased from 249 of 2636 patients (9.4%) in 1999 to 746 of 3944 (18.9%) in 2016 (P < .001). Among PWID who died of infective endocarditis, the proportion of patients younger than 35 years rose from 12.4% (n = 31/ 249) in 1999 to 37.4% (n = 279/746) in 2016 (P < .001; Figure 2) , and the proportion of white individuals rose from 60.2% (n = 150/249) in 1999 to 88.9% (n = 663/746) in 2016 (P < .001). The underlying cause of death was infective endocarditis (n = 1319; 23.5%), drug use (n = 3037; 54.2%), septicemia (ICD10 code A41; n = 86; 1.5%), stroke/intracranial hemorrhage (ICD10 codes I60-I64; n = 125; 2.2%), and ischemic heart disease (ICD10 codes I20-I25; n = 121; 2.2%).
Discussion | The opioid crisis has created a national public health emergency. Although PWID die most commonly of anoxic brain injury, 3 infective endocarditis is a potentially Although our findings appear linked to the opioid crisis, there are other putative explanations. For example, more virulent and resistant microorganisms may have increased lethality of infective endocarditis in PWID. Also, previously treated patients who had infective endocarditis who subsequently died from overdose may confound our findings. Lastly, because death certificates may lack accuracy in cause of death attribution, direct causality of infective endocarditis deaths to opioid use cannot be ascertained.
Taken together, our findings should prompt clinicians to be vigilant when treating PWID with fevers and to use a low threshold to initiate antibiotic therapy to mitigate further infective endocarditis fatalities. 
COMMENT & RESPONSE

Questioning the Associations of ω-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
To the Editor Several recent meta-analyses of randomized clinical trials report contrasting results in regards to the protective effect of dietary supplementation with ω-3 polyunsaturated fatty acids (PUFAs) on cardiovascular disease risk. Based on these data, the American Heart Association recently modulated their suggestion on ω-3 PUFA supplementation, concluding it has potential usefulness in secondary prevention patients.
1 In their meta-analysis carried out on 77 917 highrisk individuals participating in 10 trials, Aung et al 2 further
contrast the American Heart Association statement by demonstrating that ω-3 PUFAs supplementation was not associated with reduction in the risk of any vascular outcome. Because the plasma level of ω-3 PUFAs seems to be a more significant predictor of cardiovascular events than the amount assumed with diet, 3,4 the significant difference in efficacy observed in various trials could be at least partly related to the large discrepancy in the different bioavailability of the tested products. The research of new sources (eg, from arctic krill oil) and pharmaceutical forms of ω-3 PUFA (eg, ω-3 carboxylic acids) is in fact needed to detect the one with the best bioavailability and efficacy and with a parallel reduction in the production costs. 5 For these reason, the conclusion of the metaanalysis by Aung et al 2 (as the previous ones) has to be interpreted with caution. To the Editor ω-3 Polyunsaturated fatty acid (PUFA) supplementation was not associated with a lower risk for adverse cardiovascular outcome in the study by Aung et al. 1 These results are not surprising, and several issues may have affected these neutral outcomes. The GISSI-Prevenzione trial 2 demonstrated that at least 1 g per day of ω-3 PUFAs is required for cardiovascular benefit in patients postinfarction. Most of the studies in the meta-analysis by Aung et al 1 used a lower dose of ω-3
PUFAs that was insufficient for cardioprotection. Polyunsaturated fatty acids have no effects in normal patients or in those with low risk of ischemic events. Some of the studies cited included patients postinfarction optimally treated after primary angioplasty who had preserved left ventricular ejection fraction or patients who were enrolled years after an infarction; these patients have risk profiles that are vastly different from those of patients enrolled early after an acute event. In a large, contemporary, observational study of real-world patients hospitalized for acute myocardial infarction, 3 we demonstrated that a sizable proportion of patients did not undergo primary angioplasty and had reduced ejection fraction. In this cohort, early use of ω-3 PUFAs was independently associated with a robust reduction in 1-year all-cause mortality and recurrent infarction. Some trials in the meta-analysis by Aung et al 1 were too short to show any effect. Finally, the authors state that the 95% CIs cannot exclude a 7% lower risk of major cardiovascular events and a 10% lower risk of ischemic events associated with ω-3 PUFA supplementation. 1 Thus, patient risk profile, duration of treatment, and supplementation dose may all affect the efficacy of this therapy and, in turn, the conclusion of the published meta-analysis. 1 While we await the results of ongoing large randomized trials, it is prudent to continue with the American Heart Association 4 recommendation that in the first year after an infarction in patients with left ventricular dysfunction and a high arrhythmic risk, supplementation with at least 1 g per day of ω-3 PUFA remains costeffective and justified. In Reply The recent Omega-3 Treatment Trialists' Collaboration report 1 provided an updated summary of the results of 10 large randomized trials and involved almost 78 000 people treated with ω-3 fatty acid supplements for a mean of 5 years for the prevention of cardiovascular disease. The results demonstrated no significant associations of ω-3 fatty acid treatment with coronary heart disease (CHD) death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .053), nonfatal myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43), or any CHD events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). In contrast with previous meta-analyses, 2,3 this meta-analysis was conducted by the lead investigators of the individual trials and included analyses that distinguished the effects of ω-3 fatty acids on subtypes of CHD and the effects of ω-3 fatty acids on major vascular events in population subgroups (by age, sex, prior vascular disease, diabetes, or lipid levels). Cicero et al advocated for additional research on novel pharmaceutical forms of ω-3 fatty acids, such as arctic krill oil, that may have superior bioavailability. However, to our knowledge, no trials have yet assessed the efficacy of artic krill oils for prevention of cardiovascular disease. However, the results of the Omega-3 Treatment Trialists' Collaboration meta-analysis 1 provide no support for the current recommendations of the American Heart Association to use the widely used ω-3 fatty acids for prevention of fatal CHD or any major vascular disease in people with a history of CHD or at high risk of CHD. Nodari et al reported the results of a prospective study 4 suggesting that use of ω-3 fatty acids among patients under- going primary coronary angioplasty was associated with a lower risk of subsequent myocardial infarction or death from all causes, but such nonrandomized comparisons cannot exclude the effects of bias or confounding by other risk factors. The lower 95% CI used in the Omega-3 Treatment Trialists' Collaboration meta-analysis 1 indicates that the metaanalysis cannot exclude a 7% lower risk of major vascular events or 10% lower risk of any CHD event. Importantly, the meta-analysis demonstrated no difference in the effects of ω-3 fatty acids on major vascular events in any of the subgroups studied. 1 In particular, there were no differences in the effects of ω-3 fatty acids in those with or without a history of prior vascular disease.
